Ardelyx (ARDX) Competitors $4.97 +0.26 (+5.52%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ARDX vs. OPK, FLXN, NLTX, MIRM, XBIT, IMVT, OGN, RYTM, IBRX, and APLSShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include OPKO Health (OPK), Flexion Therapeutics (FLXN), Neoleukin Therapeutics (NLTX), Mirum Pharmaceuticals (MIRM), XBiotech (XBIT), Immunovant (IMVT), Organon & Co. (OGN), Rhythm Pharmaceuticals (RYTM), ImmunityBio (IBRX), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector. Ardelyx vs. OPKO Health Flexion Therapeutics Neoleukin Therapeutics Mirum Pharmaceuticals XBiotech Immunovant Organon & Co. Rhythm Pharmaceuticals ImmunityBio Apellis Pharmaceuticals Ardelyx (NASDAQ:ARDX) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Do analysts recommend ARDX or OPK? Ardelyx presently has a consensus price target of $10.42, indicating a potential upside of 109.59%. OPKO Health has a consensus price target of $2.75, indicating a potential upside of 67.68%. Given Ardelyx's higher possible upside, analysts clearly believe Ardelyx is more favorable than OPKO Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88OPKO Health 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ARDX or OPK? Ardelyx has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Which has higher valuation and earnings, ARDX or OPK? Ardelyx has higher earnings, but lower revenue than OPKO Health. Ardelyx is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$124.46M9.46-$66.07M-$0.30-16.57OPKO Health$863.50M1.30-$188.86M-$0.19-8.63 Does the MarketBeat Community favor ARDX or OPK? Ardelyx received 25 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 67.52% of users gave Ardelyx an outperform vote while only 65.84% of users gave OPKO Health an outperform vote. CompanyUnderperformOutperformArdelyxOutperform Votes53067.52% Underperform Votes25532.48% OPKO HealthOutperform Votes50565.84% Underperform Votes26234.16% Is ARDX or OPK more profitable? OPKO Health has a net margin of -18.65% compared to Ardelyx's net margin of -28.82%. OPKO Health's return on equity of -9.76% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-28.82% -46.60% -21.49% OPKO Health -18.65%-9.76%-6.46% Does the media refer more to ARDX or OPK? In the previous week, Ardelyx had 12 more articles in the media than OPKO Health. MarketBeat recorded 20 mentions for Ardelyx and 8 mentions for OPKO Health. OPKO Health's average media sentiment score of 1.01 beat Ardelyx's score of 0.03 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral OPKO Health 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ARDX or OPK? 58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 5.9% of Ardelyx shares are owned by company insiders. Comparatively, 47.3% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryOPKO Health beats Ardelyx on 11 of the 19 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-16.574.8266.7313.27Price / Sales9.46374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book7.429.636.455.92Net Income-$66.07M$154.43M$119.73M$225.73M7 Day Performance-1.97%-9.46%-5.13%-1.34%1 Month Performance-14.75%-7.27%-2.71%1.15%1 Year Performance14.78%28.13%31.08%24.02% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.0429 of 5 stars$4.97+5.5%$10.42+109.6%+23.3%$1.18B$124.46M-16.57267Short Interest ↑Analyst RevisionGap UpOPKOPKO Health4.6578 of 5 stars$1.61+2.5%N/A+14.7%$1.07B$863.50M-8.473,930Insider BuyingFLXNFlexion TherapeuticsN/A$9.12flatN/AN/A$458.93M$85.55M-4.54257NLTXNeoleukin TherapeuticsN/A$40.00-44.1%N/A+162.3%$375.92MN/A-12.8690Gap DownHigh Trading VolumeMIRMMirum Pharmaceuticals4.2693 of 5 stars$42.28+1.6%N/A+46.8%$1.99B$186.37M-18.46140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageHigh Trading VolumeXBITXBiotech1.0326 of 5 stars$7.09-2.9%N/A+80.0%$222.38M$4.01M-6.11100Positive NewsIMVTImmunovant1.6355 of 5 stars$29.27-6.0%N/A-21.0%$4.57BN/A-13.18120Positive NewsOGNOrganon & Co.4.7935 of 5 stars$15.58-1.5%N/A+37.3%$4.14B$6.26B3.0910,000Ex-DividendNews CoveragePositive NewsRYTMRhythm Pharmaceuticals3.7757 of 5 stars$64.06-2.3%N/A+73.2%$4.03B$77.43M-14.79140Insider SellingIBRXImmunityBio0.7014 of 5 stars$4.95-9.2%N/A+9.8%$3.80B$620,000.00-5.10590APLSApellis Pharmaceuticals4.501 of 5 stars$29.26-1.1%N/A-45.1%$3.68B$396.59M-14.41702 Related Companies and Tools Related Companies OPK Competitors FLXN Competitors NLTX Competitors MIRM Competitors XBIT Competitors IMVT Competitors OGN Competitors RYTM Competitors IBRX Competitors APLS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARDX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
